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Introduction
According to the nonprofit organization Breastcancer.org, approximately one in eight 
women develop breast cancer in their lifetime and breast cancer in U.S. women has the second 
highest mortality rate of all cancers, second only to lung cancer. The immune system is critical in 
the bodies response against cancer, with the chemokine receptor CXCR3 known to play a role in 
various cancers, including breast cancer. CXCR3 is expressed by a variety of immune cells, 
including but not limited to natural killer cells (NK), natural killer T cells (NKT),  CD4+ and 
CD8+ T cells, and T regulatory cells (Treg). [1; 2; 3]. CXCR3 has also been shown to be 
expressed on macrophages and CXCL10 has been shown to play a role in monocyte chemotaxis 
in vitro  [4]. These CXCR3 expressing cells migrate to specific areas of the human body through 
following chemokine gradients made up of three different ligands. The ligands associated with 
CXCR3 are CXCL9, CXCL10, and CXCL11 [1].
Previous research has shown the role of CXCR3 within other cancers, such as its role in 
promotion of tumor growth in gliomas [5]. This research has also shown that Natural killer T 
cells (NKT), which are known to express CXCR3, have been found around and infiltrating 
gliomas in higher levels than controls [5]. Other cell types that are known to express CXCR3 
have also been examined in their role against breast cancer, like natural killer cells which have 
previously been shown to play a role in suppression of tumor growth and metastasis [6]. Previous 
work has also helped characterize the leukocyte response in the tumor tissue, axillary lymph 
nodes, and peripheral blood of breast cancer patients [7]. However, even though the role played 
by immune cell types that express CXCR3 has been examined in breast cancer, the actual role of 
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CXCR3 within tumorigenesis in breast cancer has not been extensively examined. Of the 
published works, a large focus is on metastasis from the angle of tumor cells expressing CXCR3 
[8]; however, little has been published on the role of CXCR3 in the host response to breast 
cancer tumorigenesis. Instead of relying on an in vivo model to elucidate the role of CXCR3 
within breast cancer, the literature  focuses on the use of clinical samples, which do not allow for 
the accountability of environmental, genetic, or other factors [9]. 
Due to the lack of a host response focus in previous research, this project's focus is on the 
importance of CXCR3 in response to tumorigenesis from the host perspective through the use of 
an animal model. We hypothesize that CXCR3 is essential for tumor suppression due to its 
importance in the accumulation of immune cells at the site of tumorigenesis. Therefore, it is 
expected that the over-expression of CXCR3 will lead to the development of smaller tumors than 
in the wild type animal.
Methods
This project used transgenic mice that have been genetically modified to over-express the 
gene for CXCR3 in a C57Bl/6 background. These mice have been created by Dr. Oghumu as 
part of his work in Dr. Satoskar's laboratory. These transgenic mice were injected with 500,000 
cells in 100 uL of PBS per mouse of a cancerous cell line to induce tumors within the mammary 
gland tissue. Wild type mice were also injected with the same cell line to act as a control for the 
transgenic mice. The cell line being injected has a modified gene that encodes the Polyoma 
middle T oncoprotein (PyMT) inserted into its genome and are provided by Dr. Ganju's 
laboratory. The PyMT gene is an oncogene and is engineered to have the Murine Mammary 
Tumor Virus (MMTV) promoter. This MMTV promoter allows the expression of the oncogene 
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to be mammary gland specific, thereby allowing greater specificity in the type of cancer 
generated by injecting the cell line. This cell line has been shown to develop a cancer that is very 
similar to human breast cancer in development and cellular morphology, thereby proving to be a 
good model for the immune response to tumorigenesis [10].
After injection of the cancerous cell line, the tumor growth was monitored weekly. The 
tumor growth was measured with a caliper to determine the width and length of the tumor. The 
smaller measurement was designated as the width and the formula 0.52 * length * (width)2 was 
used to determine the volume. Once the tumor had grown to between 1.5 and 2 cm in length and 
width, the mice were sacrificed and analysis of the tumor and surrounding tissue was undertaken. 
This group of mice ended up being sacrificed seven weeks after the injection of the cell line.
The sacrificed animals were then dissected to extract the tumor and surrounding tissue for 
analysis. The lymph nodes and spleen were also collected to analyze the draining and migration 
of cells that occurs as part of the natural immune process. Analysis of these samples was 
conducted by flow cytometry. 
In flow cytometry, cells are exposed to antibodies that bind to specific antigens, and these 
antibodies are then detected through florescence. This florescence stems from the excitation of 
the fluorochrome on the ends of the antibodies by lasers within the flow cytometry machine, 
thereby producing detectable florescence. This technique was used to detect the lymphocyte and 
macrophage populations. CD3 in junction with CD4 and CD8 were used as markers to determine 
the CD8+ (CD3+ and CD8+) and CD4+ T (CD3+ and CD8+) cells within the samples. The NK 
marker NK1.1 and the T cell receptor marker CD3 were the antibodies used to determine the NK 
(CD3- and NK1.1+) and NKT (CD3+ and NK1.1+) cell populations. Classically activated and 
alternatively activated macrophages were also examined. The classically activated macrophages 
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were determined through staining with antibodies against the mature macrophage markers F4/80 
and CD11b. The alternatively activated macrophages populations were determined through 
antibodies against the mannose receptor (CD206), which is an alternative macrophage marker 
due to its up-regulation after IL-4 activation of the macrophage.
A repeat of this initial experiment has been started with slight modifications to the 
experimental design. The second experiment contains seven Tg and 12 WT mice, rather than the 
initial experiment's five mice per group. Also, 1,000,000 PyMT cells in 100 uL of PBS were 
injected per mouse rather than the initial experiments 500,000 cells per mouse. 
Results
The initial signs of tumor growth were detected at one and a half weeks, with the ability 
to feel a minuscule bump around the ninth nipple of three of the WT and two of the Tg mice 
(Figure 1). By the second week these tumors became measurable with the WT mice averaging a 
tumor volume of 8.9 across three mice that had measurable tumors and two mice with 
unmeasurable tumors. At this two week time point the Tg mice averaged 2.2 across two mice 
with measurable tumors and 
two mice with unmeasurable 
tumors. At the third week time 
point, the mice displayed some 
superficially noticeable tumor 
regression. The Tg mouse 
group had four mice with 
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unmeasurable but detectable tumors at three weeks, while the wild type also had four mice with 
unmeasurable tumors and a fifth mouse with a measurable tumor. The fourth week post-injection 
continued the trend of the regression of the initial tumor growth, with all five WT mice having 
unmeasurable tumors and four of the Tg mice also having unmeasurable tumors. After the fourth 
week neither of groups had mice with measurable tumors (Figure 1). These mice were not 
sacrificed until the seventh time point, because a similar experiment that utilized CXCR3 
knockout mice that was being run in-tandem with this experiment. The knockout mice had a 
tumor that grew to the tumor size limit seven weeks post-injection, and the mice from both 
experiments were then sacrificed simultaneously.
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Flow cytometry was used to more closely examine the differences in immune cell 
trafficking and populations within the WT and Tg mice, in response to tumorigenesis. Within the 
lymph node, the CD4+ and CD8+ T cell percentages of the total cells in the lymph node were 
similar between the WT and Tg mice (Figure 2). The percentage of NK and NKT cells that made 
up the lymph node population was also consistent between the WT and Tg mice groups. This 
consistency between NK and NKT levels in the two groups was also seen in the mouse spleens. 
However, the WT mice had a higher percentage of CD4+ T cells and CD8+ T cells in the spleen 
than the Tg mouse group. Flow cytometry was also used to examine the macrophage populations 
in the two groups of mice. 
In the lymph node, the Tg 
mouse group had a higher 
percentage of alternatively 
activated macrophages than 
the WT mice. Even though 
the spleen contained a significantly larger percentage of alternative macrophages than the lymph 
node, the relation between the alternative macrophage percentages of the WT and Tg mice 
groups has remained the same. Within the spleen, the Tg mice had a higher percentage of the M2 
macrophages than the WT mouse group (Figure 3). 
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This experiment was repeated with minor changes to the experimental methods, and is 
currently ongoing. This second experiment has already yielded results in the form of tumor 
volume size up to 40 days post-injection of the PyMT cell line. The Tg and WT mouse groups 
are exhibiting 
very similar 
average tumor 
volumes up to 
the 28th day. 
After this point, 
the average 
tumor volume 
is significantly 
larger in the Tg mouse group than in the WT mice (Figure 4). More results will be available from 
this second experiment upon sacrificing the animals and harvesting their organs for further 
analysis.
Discussion
The results from the first experiment suggest a role of CXCR3 within the immune 
response to tumorigenesis. While the difference between the tumor growth in the Tg and WT 
groups is noticeable, thereby suggesting CXCR3 is playing a role in the response to tumor 
growth, the difference is not a very large one. However, the WT mice did have significantly 
higher T lymphocyte percentages in the spleen, pointing towards an effect on T cell trafficking 
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by CXCR3 during tumorigenesis. Interestingly, a higher percentage of alternatively activated 
macrophages was found in both the spleen and the lymph nodes of the Tg mice combined. This 
raised level of macrophages and the knowledge that macrophages express CXCR3 further 
supports the idea of a change in immune cell trafficking within the Tg mice [4 ]. 
Combined with the immune cell population data, the tumor volumes after the 28 day time 
point in the second experiment may indicate an effect on tumorigenesis and breast cancer 
development stemming from the difference in cell trafficking due to CXCR3 expression. If a 
similar increase in alternative macrophages in the Tg mice is found in the second experiment as 
in the first experiment, then it could explain the significantly larger average tumor volumes in the 
Tg mice after the fourth week time point (28 day time point). Alternative macrophages are 
known to be immune suppressive and it has been shown that tumor-associated macrophages are 
typically alternatively activated macrophages [4; 11]. This observation would then point to 
increased immune regulatory cells trafficking to the tumor and existence in the periphery due to 
the over-expression of CXCR3. The higher trafficking of immune suppressor cells would also 
help explain the lower levels of CD4+ T cells and CD8+ T cells within the Tg mice spleens in 
comparison to the WT mice spleens.
Now that it is evident that CXCR3 over-expression is having a noticeable effect on 
tumorigenesis, it is going to be important to continue experiment two and design and execute 
more experiments to better elucidate how CXCR3 is causing this change in tumorigenesis. Due 
to the possibility of immune regulatory cells playing a role in this change, it will be important to 
examine the populations of T regulatory cells in the lymph node, spleen, and tumor. Flow 
cytometry will also need to be done on the tumor itself, to better understand the effect of cell 
trafficking on the immune cell population in and around the tumor. It may also be interesting to 
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harvest lymph nodes individually to examine whether there is a difference in the immune cell 
populations between lymph nodes local to the tumor versus sites far away from the tumor. While 
further experiments are definitely needed to gain a better idea of the role of CXCR3 in breast 
cancer tumorigenesis, this work has been a promising start with great potential.
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